Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects

YesBackgorund Prior data suggest pre-diagnostic aspirin use impacts breast tumour biology and patient outcome. Here, we employed faithful surgical resection models of HER2+ and triple-negative breast cancer (TNBC), to study outcome and response mechanisms across breast cancer subtypes. Method NOD/SCID mice were implanted with HER2+ MDA-MB-231/LN/2-4/H2N, trastuzumab-resistant HER2+ HCC1954 or a TNBC patient-derived xenograft (PDX). A daily low-dose aspirin regimen commenced until primary tumours reached ~250 mm3 and subsequently resected. MDA-MB-231/LN/2-4/H2N mice were monitored for metastasis utilising imaging. To interrogate the survival benefit of pre-treatment aspirin, 3 weeks post-resection, HCC1954/TNBC animals received standard-of-care (SOC) chemotherapy for 6 weeks. Primary tumour response to aspirin was interrogated using immunohistochemistry. Results Aspirin delayed time to metastasis in MDA-MB-231/LN/2-4/H2N xenografts and decreased growth of HER2+/TNBC primary tumours. Lymphangiogenic factors and lymph vessels number were decreased in HER2+ tumours. However, no survival benefit was seen in aspirin pre-treated animals (HCC1954/TNBC) that further received adjuvant SOC, compared with animals treated with SOC alone. In an effort to study mechanisms responsible for the observed reduction in lymphangiogenesis in HER2+ BC we utilised an in vitro co-culture system of HCC1954 tumour cells and mesenchymal stromal cells (MSC). Aspirin abrogated the secretion of VEGF-C in MSCs and also decreased the lymph/angiogenic potential of the MSCs and HCC1954 by tubule formation assay. Furthermore, aspirin decreased the secretion of uPA in HCC1954 cells potentially diminishing its metastatic capability. Conclusion Our data employing clinically relevant models demonstrate that aspirin alters breast tumour biology. However, aspirin may not represent a robust chemo-preventative agent in the HER2+ or TNBC setting.Funding is acknowledged from the Irish Cancer Society Collaborative Cancer Research Centre under BREAST- PREDICT grant CCRC13GAL (www.breas tpred ict.com). I.S.M, E.M and A.T.B, are members of the EurOPDX Consortium, and receive funding from the European Union's Horizon 2020 research and innovation programme, grant agreement no. #731105 (EurOPDX Research Infrastructure, www.europ dx.eu)

Risk thresholds for alcohol consumption : combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies

Background Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. Methods We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose-response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12.5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5.6 years [5th-95th percentile 1.04-13.5]) from 71 011 participants from 37 studies. Findings In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5.4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality risk around or below 100 g per week. Alcohol consumption was roughly linearly associated with a higher risk of stroke (HR per 100 g per week higher consumption 1.14, 95% CI, 1.10-1.17), coronary disease excluding myocardial infarction (1.06, 1.00-1.11), heart failure (1.09, 1.03-1.15), fatal hypertensive disease (1.24, 1.15-1.33); and fatal aortic aneurysm (1.15, 1.03-1.28). By contrast, increased alcohol consumption was loglinearly associated with a lower risk of myocardial infarction (HR 0.94, 0.91-0.97). In comparison to those who reported drinking >0-100-200-350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1-2 years, or 4-5 years, respectively. Interpretation In current drinkers of alcohol in high-income countries, the threshold for lowest risk of all-cause mortality was about 100 g/week. For cardiovascular disease subtypes other than myocardial infarction, there were no clear risk thresholds below which lower alcohol consumption stopped being associated with lower disease risk. These data support limits for alcohol consumption that are lower than those recommended in most current guidelines. Copyright (C) The Author(s). Published by Elsevier Ltd.Peer reviewe

Influence of gyroradius and dissipation on the Alfven-wave continuum

It is well known that in ideal magnetohydrodynamics there is a continuous spectrum of real frequencies associated with a singularity of the shear Alfven waves on the surface k/sub parallel to/v/sub A/ = omega. It is also known that the introduction of first-order gyroradius effects eliminates the continuum. In the present work we examine the influence of the full gyroradius response and of dissipation on the continuum. In the absence of dissipation we first confirm that if only first-order gyroradius effects are incorporated, the continuum disappears. However, when the full gyroradius response is included, this discrete spectrum vanishes, and a new continuum (associated with singularities at k/sub parallel to/v/sub A/ = 0) appears. The introduction of collisional dissipation removes the original MHD continuum leaving discrete modes whose frequency tends to zero with the collision rate as ..nu../sup 1/3/. collisions also remove the new continuum of the full gyroradius model leaving discrete modes whose frequency tends to zero as (log ..nu..)/sup -1/. Collisionless Landau damping has a similar effect

Comparison of the behavioral consequences and recovery patterns of largemouth bass exposed to MS-222 or electrosedation

Fish are commonly sedated to render them immobile and thus easier to handle for research, veterinary, and aquaculture practices. Since sedation itself imposes a significant challenge on the targeted fish, the selection of sedation methods that minimize physiological and behavioral disturbance and recovery time is essential. Two popular sedation methods include the chemical tricaine methanesulfonate (MS-222) and electrosedation. Although many studies have already investigated the physiological consequences of these methods, there is limited research examining the latent behavioral effects on fish. Using Largemouth Bass Micropterus salmoides as a model species, we compared the postsedation behaviors of fish that were sedated with either MS-222 or electrosedation to those of a control group exposed to the same handling protocol. Immediately after sedation, fish exposed to either treatment demonstrated lower reflex scores than the control group. Time to resume regular ventilation did not differ between chemically sedated and electrosedated fish; however, electrosedated fish regained equilibrium faster (mean ± SE = 154 ± 20 s) than fish that were exposed to MS-222 (264 ± 30 s). Locomotor activity and swimming performance were assessed at 5-, 30-, or 60-min intervals, beginning after individuals had recovered from sedation sufficiently to regain equilibrium. For all postsedation intervals, locomotor activity was two times greater in the electrosedated group than in the control and MS-222 groups. Other behavioral measures (refuge emergence time, activity level, and flight initiation distance) and swimming performance did not differ at 5, 30, or 60 min postrecovery for any of the treatment groups. Our results indicate that while both chemical and electrical sedation methods result in impairment (i.e., sedation) immediately after treatment, these behavioral effects do not persist beyond 5 min postrecovery, and the two methods have similar impacts on Largemouth Bass. However, we caution that these results cannot be extrapolated to other fish species without further study